^
Association details:
| Biomarker: | CXCL12-L |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Regimen: | (cyclophosphamide + docetaxel) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SDF-1 expression and tumor-infiltrating lymphocytes identify clinical subtypes of triple-negative breast cancer with different responses to neoadjuvant chemotherapy and survival
Published date:
10/20/2022
Excerpt:
A total of 303 TNBC patients were included in this study. The NAC regimen was weekly paclitaxel plus carboplatin (PC) for all patients….A higher pCR rate was more likely to be observed in patients with lower serum SDF-1 levels before NAC (P=0.001, OR=0.997, 95% CI: 0.996-0.999) and higher levels of TILs (P=0.005).
DOI:
10.3389/fimmu.2022.940635
